ASX biotech stock Mesoblast presents growing revenues other catalysts for a potential pull back
Written by
Varun Ratra
MSB is growing with rising revenues, advancing clinical trials, strong cash position, and expanding cell therapy programs.
Mesoblast Ltd (ASX: MSB)
on 30 April 2026 shared its quarterly activity report for the period ended March 31 2026. The company reported Ryoncil gross sales of US$35.3 million and net revenue of US$30.3 million for the quarter. Sales during February and March improved after a slower January period linked to holiday season trends. Revenue generated from Ryoncil since its launch last year is now nearing US$100 million. Net operating cash spend for the quarter was reduced to US$4.1 million due to strong receipts and careful expense management. The company finished the quarter with US$122 million in cash reserves.
Development and Regulatory Progress
MSB confirmed that patient recruitment has been completed in the Phase 3 study of rexlemestrocel-L for chronic low back pain. During its R&D event held on April 8 in New York the company discussed plans to expand the use of Ryoncil into additional adult and pediatric rare disease areas. It also shared updates on programs focused on inflammatory back pain and heart failure. The FDA cleared the study for adult SR-aGvHD and the first trial sites are expected to begin activation during the current quarter. In another important step the FDA granted Investigational New Drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy which affects about 15,000 children in the United States.
Future Cell Therapy Programs
Mesoblast also introduced its next generation mesenchymal stromal cell strategy. The company announced an exclusive worldwide license agreement for a patented CAR technology platform designed to improve the precision and strength of its cell therapy products. The platform may support future treatment opportunities in ulcerative colitis and Crohn’s disease. Mesoblast also plans to develop CAR-MSC therapies targeting Lupus Nephritis and other autoimmune diseases connected to B cells where long term immune regulation is considered important.
Phase 3 Trial
MSB on 29 April 2026 announced that recruitment targets were achieved in its pivotal Phase 3 trial evaluating rexlemestrocel-L for chronic low back pain linked to degenerative disc disease. The placebo controlled study includes more than 300 patients who will be monitored for 12 months after receiving either a single injection or a sham procedure. The trial aims to confirm earlier findings that showed reductions in pain and opioid use for up to three years. Top line study results are expected in mid-2027 followed by a planned FDA filing in Q3 2027 if outcomes are positive.
(Source: Company Rpeort)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
